Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 May;174(5):622-632.
doi: 10.7326/M20-6739. Epub 2021 Jan 26.

Thrombosis, Bleeding, and the Observational Effect of Early Therapeutic Anticoagulation on Survival in Critically Ill Patients With COVID-19

Collaborators, Affiliations
Observational Study

Thrombosis, Bleeding, and the Observational Effect of Early Therapeutic Anticoagulation on Survival in Critically Ill Patients With COVID-19

Hanny Al-Samkari et al. Ann Intern Med. 2021 May.

Erratum in

Abstract

Background: Hypercoagulability may be a key mechanism of death in patients with coronavirus disease 2019 (COVID-19).

Objective: To evaluate the incidence of venous thromboembolism (VTE) and major bleeding in critically ill patients with COVID-19 and examine the observational effect of early therapeutic anticoagulation on survival.

Design: In a multicenter cohort study of 3239 critically ill adults with COVID-19, the incidence of VTE and major bleeding within 14 days after intensive care unit (ICU) admission was evaluated. A target trial emulation in which patients were categorized according to receipt or no receipt of therapeutic anticoagulation in the first 2 days of ICU admission was done to examine the observational effect of early therapeutic anticoagulation on survival. A Cox model with inverse probability weighting to adjust for confounding was used.

Setting: 67 hospitals in the United States.

Participants: Adults with COVID-19 admitted to a participating ICU.

Measurements: Time to death, censored at hospital discharge, or date of last follow-up.

Results: Among the 3239 patients included, the median age was 61 years (interquartile range, 53 to 71 years), and 2088 (64.5%) were men. A total of 204 patients (6.3%) developed VTE, and 90 patients (2.8%) developed a major bleeding event. Independent predictors of VTE were male sex and higher D-dimer level on ICU admission. Among the 2809 patients included in the target trial emulation, 384 (11.9%) received early therapeutic anticoagulation. In the primary analysis, during a median follow-up of 27 days, patients who received early therapeutic anticoagulation had a similar risk for death as those who did not (hazard ratio, 1.12 [95% CI, 0.92 to 1.35]).

Limitation: Observational design.

Conclusion: Among critically ill adults with COVID-19, early therapeutic anticoagulation did not affect survival in the target trial emulation.

Primary funding source: None.

PubMed Disclaimer

Conflict of interest statement

Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M20-6739.

Figures

Visual Abstract.
Visual Abstract.. Early Anticoagulation in COVID-19
Hypercoagulability may be a key mechanism of death in patients with COVID-19. This cohort study evaluated the incidence of venous thromboembolism and major bleeding in critically ill patients with COVID-19 and examined the observational effect of early therapeutic anticoagulation on survival.
Figure 1.
Figure 1.. Flow diagram for target trial emulation of therapeutic anticoagulation.
COVID-19 = coronavirus disease 2019; DVT = deep venous thrombosis; ECMO = extracorporeal membrane oxygenation; ICU = intensive care unit; PE = pulmonary embolism.
Figure 2.
Figure 2.. Target trial emulation.
Survival in patients who received therapeutic anticoagulation in the first 2 days of ICU admission compared with those who did not. AC = anticoagulation; ICU = intensive care unit.
Figure 3.
Figure 3.. Results of sensitivity and subgroup analyses.
Shown are the hazard ratios for survival according to early initiation of therapeutic AC versus no early initiation of therapeutic AC in the primary analysis, the sensitivity analyses, and across subgroups. AC = anticoagulation; HR = hazard ratio; ICU = intensive care unit.

Comment in

References

    1. Tremblay D , van Gerwen M , Alsen M , et al. Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study [Letter]. Blood. 2020;136:144-147. [PMID: ] doi:10.1182/blood.2020006941 - DOI - PMC - PubMed
    1. Lala A , Johnson KW , Januzzi JL , et al; Mount Sinai COVID Informatics Center. Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection. J Am Coll Cardiol. 2020;76:533-546. [PMID: ] doi:10.1016/j.jacc.2020.06.007 - DOI - PMC - PubMed
    1. Cui S , Chen S , Li X , et al. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18:1421-1424. [PMID: ] doi:10.1111/jth.14830 - DOI - PMC - PubMed
    1. Klok FA , Kruip MJHA , van der Meer NJM , et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145-147. [PMID: ] doi:10.1016/j.thromres.2020.04.013 - DOI - PMC - PubMed
    1. Fox SE , Akmatbekov A , Harbert JL , et al. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir Med. 2020;8:681-686. [PMID: ] doi:10.1016/S2213-2600(20)30243-5 - DOI - PMC - PubMed

Publication types

MeSH terms